Breaking News Instant updates and real-time market news.

SNA

Snap-On

, TMUS

T-Mobile

$62.59

-0.19 (-0.30%)

09:40
03/22/18
03/22
09:40
03/22/18
09:40

Unusually active option classes on open March 22nd

Unusual total active option classes on open include: Snap on (SNA), Direxion Daily S&P Bear (SPXS), T Mobile (TMUS), AbbVie (ABBV), iShares Trust Barclays 20 Year Treasury Bond Fund (TLT), Fedex (FDX), iShares Silver Trust (SLV), Facebook (FB), Baidu (BIDU), and ProShares Ultra VIX Short Term Futures (UVXY).

SNA

Snap-On

TMUS

T-Mobile

$62.59

-0.19 (-0.30%)

ABBV

AbbVie

TLT

iShares 20+ Year Treasury Bond Fund

$119.08

0.13 (0.11%)

FDX

FedEx

SLV

iShares Silver Trust

FB

Facebook

$169.39

1.24 (0.74%)

BIDU

Baidu

$250.05

-4.41 (-1.73%)

UVXY

ProShares Trust Ultra VIX Short Term Futures ETF

  • 22

    Mar

  • 25

    Mar

  • 11

    Apr

  • 10

    May

SNA Snap-On

01/29/18
BARD
01/29/18
NO CHANGE
Target $220
BARD
Outperform
Snap-On price target raised to $220 from $184 at Baird
Baird analyst David Leiker raised his price target on Snap-On to $220 from $184 as he believes Q4 will be an inflection to positive organic growth while the favorable trends could support the current reversal in sentiment/valuation throughout 2018. Leiker reiterated his Outperform rating on Snap-On shares.
08/22/17
BARD
08/22/17
NO CHANGE
Target $197
BARD
Outperform
Snap-On weakness a buying opportunity, says Baird
Baird analyst David Leiker said the recent weakness in Snap-On shares following a competitor's downgrade has brought a buying opportunity. He sees demand trends across the company as positive and growing and thinks industry and end-market demand is still healthy. Leiker reiterated his Outperform rating and $197 price target on Snap-On shares, saying the business is positioned for better growth in quarters ahead and views the current valuation as attractive for long-term holders.
10/18/17
BARD
10/18/17
NO CHANGE
Target $184
BARD
Outperform
Snap-On long-term story intact, says Baird
Baird analyst David Leiker noted the "short story" on Snap-On remains pervasive, but he believes a lot of bad news has already been priced into the stock. With valuations at 5-10 year lows, he believes the long-term story remains intact with strong ROIC and stable growth. He said he would be an aggressive buyer of the shares following its Q3 report. Leiker maintained his Outperform rating and $184 price target on Snap-On shares.
10/23/17
BRRR
10/23/17
UPGRADE
BRRR
Outperform
Snap-On upgraded to Outperform from Market Perform at Barrington
Barrington analyst Gary Prestopino upgraded Snap-On to Outperform with a $180-$190 price target range. Following the company's better than expected Q3 results, the analyst sees a "gradual rebound" in the company's Tools Group results in 2018. He likes the current valuation and is positive on the long-term outlook for vehicle repair.
TMUS T-Mobile
$62.59

-0.19 (-0.30%)

03/13/18
GUGG
03/13/18
INITIATION
Target $80
GUGG
Buy
T-Mobile initiated with a Buy at Guggenheim
Guggenheim analyst Mike McCormack initiated coverage of the Telecom Services space, naming T-Mobile as his Best Idea in the group, noting that it has added about 12.2M subscribers in the last 3 years by taking share, which he sees as "the only driver of meaningful growth for the industry." He started T-Mobile with a Buy rating and $80 price target.
03/08/18
MSCO
03/08/18
NO CHANGE
Target $74
MSCO
Overweight
T-Mobile likely to announce 'major' increase to buyback, says Morgan Stanley
Following T-Mobile CFO Braxton Carter's presentation at the firm's conference yesterday, Morgan Stanley analyst Simon Flannery said he expects T-Mobile will announce a "major" increase in its stock repurchase program with its Q1 earnings report in early May. He thinks the company could announce a total three year buyback of $7.5B-$12B, including $1.5B already underway, which he notes would be equivalent to 14%-22% of the current market cap. The market was "underwhelmed" by the original $1.5B repurchase program and absent an update he thinks the stock could trade below $60. However, he thinks the stock could trade closer to $70 if the buyback is near $12B, or significant enough to reduce the float by more than 50%. Flannery maintains an Overweight rating and $74 price target on T-Mobile shares.
03/13/18
GUGG
03/13/18
INITIATION
Target $58
GUGG
Buy
Verizon initiated with a Buy at Guggenheim
Guggenheim analyst Mike McCormack initiated coverage of the Telecom Services space, naming T-Mobile (TMUS) as his Best Idea in the group, but stating that scale remains an advantage in wireless and he is also bullish on AT&T (T) and Verizon (VZ). He started Verizon with a Buy rating and $58 price target.
03/13/18
03/13/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Verizon (VZ), AT&T (T), and T-Mobile (TMUS) were initiated with a Buy at Guggenheim while Sprint (S) was initiated with a Sell. 2. CNO Financial (CNO) initiated with an Outperform at William Blair. 3. GMS Inc. (GMS) initiated with a Buy at Nomura Instinet. 4. Core Laboratories (CLB) assumed with a Neutral at Piper Jaffray. 5. Cutera (CUTR) initiated with an Overweight at Stephens. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
ABBV AbbVie

03/08/18
PIPR
03/08/18
NO CHANGE
Target $138
PIPR
Overweight
AbbVie shares can 'continue to work,' says Piper Jaffray
After hosting a meeting with investors at AbbVie's (ABBV) headquarters this week, Piper Jaffray analyst Christopher Raymond believes the shares can "continue to work." The analyst believes the stock can continue outperforming on "solid" commercial and clinical performance. Management expressed no urgency for a larger commercial or late-stage acquisition, Raymond tells investors in a research note. The analyst says he's glad he never wrote that AbbVie for Biogen (BIIB) research note. He keeps an Overweight rating on AbbVie.
02/23/18
OPCO
02/23/18
NO CHANGE
Target $110
OPCO
Outperform
Neurocrine 'going for gold,' has 'Midas Touch,' says Oppenheimer
Oppenheimer analyst Jay Olson raised his price target on Neurocrine shares to $110 from $100, citing the positive Phase 3 study results for elagolix in the treatment of uterine fibroids by Neurocrine's collaborator AbbVie (ABBV). Additionally, Olson cited last week's disclosure that the FDA will not require a Phase 3 study in the U.S. for opicapone for the price target increase. Olson told investors in a research note called "Going for Gold -- This Team Has the Midas Touch" that both of these updates are seen as "key de-risking events" and raise the probability of success for both elagolix and opicapone to 90% from 60%. Olson has an Outperform rating on Neurocrine shares.
02/22/18
NEED
02/22/18
NO CHANGE
Target $110
NEED
Buy
Neurocrine price target raised to $110 from $95 at Needham
Needham analyst Alan Carr raised his price target on Neurocrine (NBIX) to $110 and kept his Buy rating on the stock. Carr cites the positive top-line results from the first of two phase 3 trials of elagolix by Neurocrine's collaborator AbbVie (ABBV) as well as last week's disclosure that the FDA will not require another phase 3 efficacy trial for opicapone. The analyst notes that the added timeline clarity will likely translate into the opicapone NDA submission in the first half of 2019 and a launch in mid-2020.
02/21/18
PIPR
02/21/18
NO CHANGE
PIPR
Overweight
Piper says 'hard to quibble with' elagolix efficacy, keeps AbbVie at Overweight
After AbbVie reported that one of its two Phase 3 trials of elagolix in patients with uterine fibroids met its primary efficacy endpoint and all ranked secondary endpoints, Piper Jaffray analyst Christopher Raymond said it was "hard to quibble with the efficacy data." He expects to see 12-month data from both trials later this year or early next, which would set up for a potential uterine fibroids launch in 2020. Raymond, who said he "would not be shocked" if his revenue estimates in this indication prove conservative, keeps an Overweight rating on AbbVie.
TLT iShares 20+ Year Treasury Bond Fund
$119.08

0.13 (0.11%)

FDX FedEx

03/21/18
SPHN
03/21/18
NO CHANGE
Target $306
SPHN
Overweight
Stephens still confident in FedEx's ability to earn $20+ in EPS in FY20
Stephens analyst Jack Atkins reiterated his Overweight rating and $306 price target on FedEx following the company's Q3 results, telling investors in a research note that while there were "a lot of moving pieces," the company's Q4 outlook is "encouraging" and that his confidence in FedEx's ability to earn $20+ in EPS in fiscal 2020 has not changed. Additionally, Atkins said FedEx Ground margins appear to have turned a corner, contenting that concerns held by some of a material capex step up in fiscal 2019 "appear unfounded."
03/21/18
FBCO
03/21/18
NO CHANGE
Target $306
FBCO
Outperform
FedEx price target lowered to $306 from $314 at Credit Suisse
Credit Suisse analyst Allison Landry lowered her price target for FedEx to $306 from $314 saying that a higher discount rate more than offsets higher base year EBIT in her DCF model. The analyst reiterates an Outperform rating on the shares.
03/21/18
BMOC
03/21/18
NO CHANGE
Target $300
BMOC
Outperform
FedEx Q3 results reflect strong demand and high price growth, says BMO Capital
BMO Capital analyst Fadi Chamoun kept his Outperform rating and $300 price target on FedEx following the company's "messy" Q3 results. Chamoun notes that above-consensus revenues reflected strong demand and pricing growth was at its highest levels in years, even as EBIT of $1.1B was below the expected $1.3B on weaker than expected results in the Express segment. The analyst is also positive on the company's progress in Ground operating margins and stable capital expenditures supporting higher free cash flows. Chamoun raises his FY18 EPS view to $15.24 from $14.04 and revenue outlook to $65.3B from $64.5B.
03/21/18
03/21/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Myriad Genetics (MYGN) upgraded to Equal Weight from Underweight at Morgan Stanley with analyst Steve Beuchaw citing share price underperformance and improving cancer testing survey share trends. 2. FedEx (FDX) upgraded to Buy from Hold at Stifel with analyst David Ross saying he likes the company's "general earnings trajectory" following third quarter results. 3. Children's Place (PLCE) upgraded to Buy from Neutral at Citi with analyst Kate McShane saying the company reported another quarter of industry leading comps. 4. Catalent (CTLT) upgraded to Outperform from Market Perform at Raymond James with analyst Michael Baker saying shares are down 15% following the first quarter report on tough second half 2018 comps, and believes shares reflect this dynamic now. 5. WellCare (WCG) upgraded to Outperform from Market Perform at Wells Fargo with analyst Peter Costa saying he believes WellCare could benefit from significantly higher favorable prior period development in 2018. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
SLV iShares Silver Trust

FB Facebook
$169.39

1.24 (0.74%)

03/22/18
RBCM
03/22/18
NO CHANGE
Target $250
RBCM
Outperform
Facebook pullback offers 'very compelling' opportunity, says RBC Capital
RBC Capital analyst Mark Mahaney keeps his Outperform rating and $250 price target on Facebook amid the pullback in the stock, saying he would recommend buying into the weakness while maintaining that the company is still the "Best Growth Story in Tech". Mahaney cites an "almost unanimous" opinion from executives at technology companies and consumer internet companies that the latest data controversies would have no material impact on the relevance and attractiveness of Facebook's marketing platform. That being said, Mahaney also warns that user and engagement growth could suffer in Q1-Q2 amid the negative media attention brought on the company. Still, the analyst believes that at $170 price point, Facebook is trading at a valuation trough, and the medium-to-long term risk-reward on the stock is "downright compelling".
03/22/18
ARGS
03/22/18
NO CHANGE
Target $237
ARGS
Buy
Facebook user growth may slow but operational results still strong, says Argus
Argus analyst Joseph Bonner writes that the headline risk for Facebook has increased amid revelations of the Russian government using the platform to influence U.S. elections and the latest Cambridge Analytica data management scandal. Bonner adds that the scandals have led to the recent stock price sell off and may still lead to "material regulatory action" against the company which will hurt user growth over time and pose "the most serious risk". Having said that, the analyst maintains his Buy rating and $237 price target on Facebook, stating that the company's operational results have remained strong while forecasting a long-term earnings growth rate of 24% and a 22% average EPS growth over the next two years.
03/22/18
BOFA
03/22/18
NO CHANGE
Target $230
BOFA
Buy
Facebook price target lowered to $230 from $265 at BofA/Merrill
BofA/Merrill analyst Justin Post lowered his price target on Facebook to $230 and kept his Buy rating in the wake of the Cambridge Analytica data management scandal. Post states that Facebook CEO Zuckerberg made a "reasonable" statement to the media in response, acknowledging the company's responsibility in protecting user data, disclosing fixes that have been in place for years, and promising to make additional changes. However, the analyst contends that some near term impact on platform usage can be expected, and the most recent vocal critics of the breach will not be appeased. While not aware of any advertisers publicly disclosing intentions of reduced spending on Facebook marketing, Post points to the "onslaught" of negative headlines and a trending #deleteFacebook hashtag.
03/22/18
STFL
03/22/18
NO CHANGE
Target $168
STFL
Hold
Stifel sees echoes of eBay in Facebook plight, lowers price target to $168
Stifel analyst Scott Devitt lowered his price target on Facebook (FB) shares to $168 from $195, stating that the company's current plight reminds him of eBay (EBAY) in 2004. Both are unstructured content businesses built on trust that lost that trust before implementing policies to add structure and process, Devitt tells investors. He adds: "Just like PayPal was going to save eBay, Instagram may save Facebook...eventually." In making the comparison, Devitt also noted that Facebook is much bigger than eBay was and the damage currently being done at Facebook by its issues is potentially more significant. The analyst keeps a Hold rating on Facebook shares.
BIDU Baidu
$250.05

-4.41 (-1.73%)

02/15/18
02/15/18
UPGRADE
Target $280

Overweight
Baidu upgraded on expected search growth reacceleration at Morgan Stanley
As previously reported, Morgan Stanley analyst Grace Chen upgraded Baidu to Overweight from Equal Weight, citing expectations for search sales reacceleration in 2018, the potential catalyst of the iQiyi IPO and the long-term potential contributions from AI. After the company's recent Q4 beat and Q1 revenue guidance, Chen raised her price target on Baidu to $280 from $240.
02/15/18
02/15/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Bristol-Myers (BMY) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst David Risinger saying he has become more optimistic on the immuno-oncology Opdivo + Yervoy combo in first-line lung cancer, which he notes is the largest cancer market. 2. Salesforce (CRM) upgraded to Buy from Hold at Jefferies with analyst John DiFucci saying recent field checks indicate continued strong enterprise traction as well improved commercial segment momentum, likely due to moderating Microsoft (MSFT) competition. 3. Credit Suisse (CS) upgraded to Buy from Hold at Societe Generale. 4. FMC Corporation (FMC) upgraded to Buy from Neutral at Seaport Global with analyst Michael Harrison saying he sees near-term catalysts from the Ag market recovery and secular growth in lithium, which the company plans to spinoff. 5. Baidu (BIDU) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Grace Chen citing expectations for search sales reacceleration in 2018, the potential catalyst of the iQiyi IPO and the long-term potential contributions from AI. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/15/18
DBAB
03/15/18
INITIATION
Target $319
DBAB
Buy
Baidu initiated with a Buy at Deutsche Bank
Deutsche Bank analyst Han Joon Kim started Baidu with a Buy rating and $319 price target. The firm at the end of last year rated the shares a Hold. The analyst says that while Baidu may not be the fastest growing internet company in China, it is one of the "strongest R&D players in the market." He expects more focused execution on the core business and thinks the stock will "break out" over time.
02/14/18
MSCO
02/14/18
UPGRADE
MSCO
Overweight
Baidu upgraded to Overweight from Equal Weight at Morgan Stanley
UVXY ProShares Trust Ultra VIX Short Term Futures ETF

TODAY'S FREE FLY STORIES

EEM

MSCI Emerging Markets Index

$47.86

-0.28 (-0.58%)

06:34
04/20/18
04/20
06:34
04/20/18
06:34
Technical Analysis
MSCI Emerging Markets Index: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIIB

Biogen

$266.01

-2.03 (-0.76%)

, IONS

Ionis Pharmaceuticals

$45.85

-0.22 (-0.48%)

06:34
04/20/18
04/20
06:34
04/20/18
06:34
Hot Stocks
Biogen, Ionis Pharmaceuticals expand drug development collaboration »

Biogen (BIIB) and Ionis…

BIIB

Biogen

$266.01

-2.03 (-0.76%)

IONS

Ionis Pharmaceuticals

$45.85

-0.22 (-0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 18

    May

  • 21

    May

  • 23

    May

  • 30

    May

  • 06

    Jul

HON

Honeywell

$148.36

-1.035 (-0.69%)

06:34
04/20/18
04/20
06:34
04/20/18
06:34
Earnings
Honeywell raises FY18 EPS view to $7.85-$8.05 from $7.75-$8.00, consensus $7.98 »

Raises FY18 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

  • 03

    May

  • 25

    Jun

DHT

DHT Holdings

$3.87

0.075 (1.98%)

06:34
04/20/18
04/20
06:34
04/20/18
06:34
Downgrade
DHT Holdings rating change  »

DHT Holdings downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EWW

iShares MSCI Mexico

$52.53

-1.61 (-2.97%)

06:34
04/20/18
04/20
06:34
04/20/18
06:34
Technical Analysis
iShares MSCI Mexico: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$13.99

0.33 (2.42%)

06:34
04/20/18
04/20
06:34
04/20/18
06:34
Hot Stocks
Breaking Hot Stocks news story on General Electric »

GE CEO: No change to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

  • 25

    Apr

TCEHY

Tencent

, JD

JD.com

$38.88

-1.31 (-3.26%)

06:34
04/20/18
04/20
06:34
04/20/18
06:34
Periodicals
Tencent, JD.com lead $437M investment in LeEco's smart TV unit, FT reports »

Tencent (TCEHY) and…

TCEHY

Tencent

JD

JD.com

$38.88

-1.31 (-3.26%)

LNVGY

Lenovo

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$13.99

0.33 (2.42%)

06:33
04/20/18
04/20
06:33
04/20/18
06:33
Hot Stocks
Breaking Hot Stocks news story on General Electric »

GE CEO: Making progress…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

  • 25

    Apr

GE

General Electric

$13.99

0.33 (2.42%)

06:33
04/20/18
04/20
06:33
04/20/18
06:33
Hot Stocks
Breaking Hot Stocks news story on General Electric »

General Electric CEO:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

  • 25

    Apr

MINI

Mobile Mini

$45.60

-0.1 (-0.22%)

06:33
04/20/18
04/20
06:33
04/20/18
06:33
Earnings
Mobile Mini reports Q1 adjusted EPS 33c, consensus 34c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

  • 20

    Apr

  • 23

    Apr

  • 24

    Apr

GE

General Electric

$13.99

0.33 (2.42%)

06:33
04/20/18
04/20
06:33
04/20/18
06:33
Earnings
General Electric reports Q1 adjusted EPS 16c, consensus 12c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

  • 25

    Apr

GE

General Electric

$13.99

0.33 (2.42%)

06:32
04/20/18
04/20
06:32
04/20/18
06:32
Hot Stocks
Breaking Hot Stocks news story on General Electric »

General Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

  • 25

    Apr

ELY

Callaway Golf

$16.47

0.075 (0.46%)

06:32
04/20/18
04/20
06:32
04/20/18
06:32
Recommendations
Callaway Golf analyst commentary  »

Callaway recent weakness…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UUP

PowerShares DB US Dollar Index Up

$23.58

0.075 (0.32%)

06:32
04/20/18
04/20
06:32
04/20/18
06:32
Technical Analysis
PowerShares DB US Dollar Index Up: Pivot points, pivot high broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$13.99

0.33 (2.42%)

06:32
04/20/18
04/20
06:32
04/20/18
06:32
Earnings
Breaking Earnings news story on General Electric »

General Electric reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

  • 25

    Apr

HON

Honeywell

$148.36

-1.035 (-0.69%)

06:32
04/20/18
04/20
06:32
04/20/18
06:32
Earnings
Honeywell reports Q1 EPS ex-items $1.95, consensus $1.91 »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

  • 03

    May

  • 25

    Jun

SYF

Synchrony

$35.35

0.46 (1.32%)

06:32
04/20/18
04/20
06:32
04/20/18
06:32
Hot Stocks
Synchrony reports Q1 net interest margin 16.05% »

Return on assets was 2.7%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

  • 30

    May

FB

Facebook

$168.11

1.73 (1.04%)

06:31
04/20/18
04/20
06:31
04/20/18
06:31
Periodicals
Auditor clears Facebook despite Cambridge Analytica leak, WSJ reports »

PricewaterhouseCoopers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

CFG

Citizens Financial

$41.86

0.84 (2.05%)

06:31
04/20/18
04/20
06:31
04/20/18
06:31
Earnings
Citizens Financial reports Q1 EPS 78c, consensus 76c »

Reports Q1 revenue $1.5B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

  • 20

    Jul

  • 19

    Oct

SYF

Synchrony

$35.35

0.46 (1.32%)

06:31
04/20/18
04/20
06:31
04/20/18
06:31
Earnings
Breaking Earnings news story on Synchrony »

Synchrony reports Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

  • 30

    May

UDN

PowerShares DB US Dollar Index Down

06:31
04/20/18
04/20
06:31
04/20/18
06:31
Technical Analysis
PowerShares DB US Dollar Index Down: Pivot points, pivot low broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$172.79

-5.05 (-2.84%)

, LPL

LG Display

$11.71

-0.325 (-2.70%)

06:30
04/20/18
04/20
06:30
04/20/18
06:30
Periodicals
Apple hits a snag in diversification of screen suppliers, WSJ says »

According to the Wall…

AAPL

Apple

$172.79

-5.05 (-2.84%)

LPL

LG Display

$11.71

-0.325 (-2.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

PF

Pinnacle Foods

$55.20

-1.48 (-2.61%)

, CAG

Conagra Brands

$36.64

-0.52 (-1.40%)

06:28
04/20/18
04/20
06:28
04/20/18
06:28
Recommendations
Pinnacle Foods, Conagra Brands, Kraft Heinz analyst commentary  »

Pinnacle Foods is a…

PF

Pinnacle Foods

$55.20

-1.48 (-2.61%)

CAG

Conagra Brands

$36.64

-0.52 (-1.40%)

KHC

Kraft Heinz

$59.71

-1.09 (-1.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 03

    May

AAPL

Apple

$172.79

-5.05 (-2.84%)

06:27
04/20/18
04/20
06:27
04/20/18
06:27
Periodicals
Apple chief denies speculation the company could merge iOS, MacOS, SMH reports »

Amid rumors that Apple is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

LONE

Lonestar Resources

$4.95

0.04 (0.81%)

06:25
04/20/18
04/20
06:25
04/20/18
06:25
Syndicate
Breaking Syndicate news story on Lonestar Resources »

Lonestar Resources files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.